RECRUITING

The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study

Conditions

Toxicity Radiation Toxicity GI cancer Urinary cancer Gynecological Cancer

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to assess and compare GI toxicity from RT between subjects who receive therapeutic SCFA and those who receive placebo, in hopes of identifying a safe, low-cost therapeutic to reduce GI toxicity from therapeutic or environmental radiation.

Official Title

LCCC2032: The Effects of Short Chain Fatty Acid Supplementation on the Quality of Life and Treatment-related Toxicities in Subjects Receiving Abdominopelvic Radiotherapy: A Randomized Controlled Study

Quick Facts

Study Start:2023-12-15

Study Completion:2030-05

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT04700527

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information. Consent for the use of any residual material from biopsy and/or surgical resection (archival tissue) and serial blood draws will be required for enrollment. * ≥ 18 years of age on day of signing informed consent. * ECOG performance score ≤ 2 * Subjects with histological or cytological evidence/confirmation of GI, urologic or gynecologic malignancy that will be treated with minimum dose of 40Gy (equivalent dose in 2Gy per fraction or EQD2) via 3D conformal fields or IMRT to abdomen or pelvis (multimodality treatment with surgery, chemotherapy is permissible) * Subjects may have had prior chemotherapy or surgery. * Subjects deemed healthy for study inclusion by the treating physician based on the laboratory values at screening and general health status. * Prior cancer treatment must be completed at least 14 days prior to registration and the subject must have recovered from all reversible acute toxic effects of the regimen (other than alopecia) to ≤ Grade 1 or baseline. * Females of childbearing potential must have a negative urine pregnancy test within 14 days prior to simulation. NOTE: Females are considered of childbearing potential unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are naturally postmenopausal for at least 12 consecutive months. Documentation of postmenopausal status must be provided. * Females of childbearing potential must be willing to abstain from heterosexual activity or to use 2 forms of effective methods of contraception from the time of informed consent until 14 or 28 days after treatment discontinuation. The two contraception methods can be comprised of two barrier methods, or a barrier method plus a hormonal method or an intrauterine device that meets \< 1% failure rate for protection from pregnancy in the product label. * Male subjects with female partners of childbearing potential must have had a prior vasectomy or agree to use an adequate method of contraception (i.e., double barrier method: condom plus spermicidal agent) starting with the first dose of study therapy through 14-28 days after the last dose of study therapy. * Subjects is willing and able to comply with study procedures based on the judgement of the investigator or protocol designee.	* Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study). * Prior abdominopelvic RT * History of inflammatory bowel disease or GI motility disorder * Grade 2 or higher diarrhea at baseline unless deemed by the investigator to be caused by laxatives prescribed for symptomatic partial obstruction * Concurrent use of histone deacetylase inhibitors (vorinostat) * Baseline hypernatremia defined as serum sodium concentration \>145 mEg/L * Creatinine clearance \< 50 mL/min * Congestive heart failure * On a salt restricted diet for medical indications * Severe nut allergy * Active infection requiring systemic therapy. * Active central nervous system (CNS) metastases * Treatment with any investigational drug other than the drugs in this study and subjects may not be on another clinical trial. * Subject is receiving prohibited medications or treatments as listed in section 5.6 of the protocol that cannot be discontinued/replaced by an alternative therapy.

Inclusion Criteria

Exclusion Criteria

* Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information. Consent for the use of any residual material from biopsy and/or surgical resection (archival tissue) and serial blood draws will be required for enrollment.
* ≥ 18 years of age on day of signing informed consent.
* ECOG performance score ≤ 2
* Subjects with histological or cytological evidence/confirmation of GI, urologic or gynecologic malignancy that will be treated with minimum dose of 40Gy (equivalent dose in 2Gy per fraction or EQD2) via 3D conformal fields or IMRT to abdomen or pelvis (multimodality treatment with surgery, chemotherapy is permissible)
* Subjects may have had prior chemotherapy or surgery.
* Subjects deemed healthy for study inclusion by the treating physician based on the laboratory values at screening and general health status.
* Prior cancer treatment must be completed at least 14 days prior to registration and the subject must have recovered from all reversible acute toxic effects of the regimen (other than alopecia) to ≤ Grade 1 or baseline.
* Females of childbearing potential must have a negative urine pregnancy test within 14 days prior to simulation. NOTE: Females are considered of childbearing potential unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are naturally postmenopausal for at least 12 consecutive months. Documentation of postmenopausal status must be provided.
* Females of childbearing potential must be willing to abstain from heterosexual activity or to use 2 forms of effective methods of contraception from the time of informed consent until 14 or 28 days after treatment discontinuation. The two contraception methods can be comprised of two barrier methods, or a barrier method plus a hormonal method or an intrauterine device that meets \< 1% failure rate for protection from pregnancy in the product label.
* Male subjects with female partners of childbearing potential must have had a prior vasectomy or agree to use an adequate method of contraception (i.e., double barrier method: condom plus spermicidal agent) starting with the first dose of study therapy through 14-28 days after the last dose of study therapy.
* Subjects is willing and able to comply with study procedures based on the judgement of the investigator or protocol designee.

* Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).
* Prior abdominopelvic RT
* History of inflammatory bowel disease or GI motility disorder
* Grade 2 or higher diarrhea at baseline unless deemed by the investigator to be caused by laxatives prescribed for symptomatic partial obstruction
* Concurrent use of histone deacetylase inhibitors (vorinostat)
* Baseline hypernatremia defined as serum sodium concentration \>145 mEg/L
* Creatinine clearance \< 50 mL/min
* Congestive heart failure
* On a salt restricted diet for medical indications
* Severe nut allergy
* Active infection requiring systemic therapy.
* Active central nervous system (CNS) metastases
* Treatment with any investigational drug other than the drugs in this study and subjects may not be on another clinical trial.
* Subject is receiving prohibited medications or treatments as listed in section 5.6 of the protocol that cannot be discontinued/replaced by an alternative therapy.

Contacts and Locations

Study Contact

Flora Danquah

CONTACT

9849748441

flora_danquah@med.unc.edu

Principal Investigator

Shivani Sud, MD

PRINCIPAL_INVESTIGATOR

UNC

Study Locations (Sites)

Flora Danquah

Chapel Hill, North Carolina, 27599

United States

Collaborators and Investigators

Sponsor: UNC Lineberger Comprehensive Cancer Center

Shivani Sud, MD, PRINCIPAL_INVESTIGATOR, UNC

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-12-15

Study Completion Date2030-05

Study Record Updates

Study Start Date2023-12-15

Study Completion Date2030-05

Terms related to this study

Keywords Provided by Researchers

GI cancer
Urinary cancer
Gynecological Cancer

Additional Relevant MeSH Terms

Toxicity
Radiation Toxicity